{
    "nctId": "NCT01419197",
    "briefTitle": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy",
    "officialTitle": "A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 602,
    "primaryOutcomeMeasure": "Progression-free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult participants \u2265 18 years of age.\n* Histologically or cytologically documented breast cancer.\n* Metastatic or unresectable locally advanced/recurrent breast cancer.\n* HER2-positive disease by prospective laboratory confirmation.\n* Disease progression on the last regimen received as defined by the investigator.\n* Prior treatment with an trastuzumab, a taxane, and lapatinib.\n* Disease progression after at least two regimens of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.\n* Adequate organ function, as evidenced by laboratory results.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Left ventricular ejection fraction (LVEF) \u2265 50% by echocardiogram or multi gated acquisition scan.\n\nExclusion Criteria:\n\n* Chemotherapy \u2264 21 days before first study treatment.\n* Trastuzumab \u2264 21 days before first study treatment.\n* Lapatinib \u2264 14 days before first study treatment.\n* Prior enrollment in a trastuzumab emtansine containing study, regardless whether the patient received prior trastuzumab emtansine.\n* Brain metastases that are untreated or symptomatic, or require any radiation, surgery or corticosteroid therapy to control symptoms within 1 month of randomization.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}